BetterComp Secures $33M Series A to Expand into New Markets & Advance AI in Compensation Practices
New funding led by Ten Coves Capital will advance BetterComp's mission to modernize compensation management for enterprises worldwide
Article content
WALNUT CREEK, Calif. — BetterComp, a leading provider of compensation management software, today announced its $33M Series A funding round, led by Ten Coves Capital. The investment will fuel BetterComp's continued growth and innovation, enhance its AI-powered market pricing and pay recommendation capabilities, expand into new product adjacencies, and scale operations to better serve a rapidly growing global customer base.
Article content
Employee compensation is the single largest expense for most businesses, yet compensation teams in large organizations often rely on point solutions and legacy, disjointed platforms developed decades ago. BetterComp disrupts this status quo by providing a modern, user-friendly platform supported by a dedicated team of domain experts. Its cutting-edge technology delivers significant time savings and AI-driven insights, enabling compensation professionals to make faster, more accurate pay decisions aligned with evolving talent strategies and regulatory requirements.
Article content
BetterComp was founded in 2019 by Alan Miegel, Sandra Leon, and Derek Watson. With more than 40 years of combined experience in the compensation industry, the co-founders launched BetterComp to provide an agile and adaptable platform capable of scaling market pricing processes.
Article content
'We spent years watching HR departments benefit from consistent advancements in technology that made their roles more seamless and agile,' said Alan Miegel, co-founder and CEO of BetterComp. 'When we founded BetterComp, our goal was to bring similar innovation to compensation departments, which have historically lacked this kind of progress. After bootstrapping the business since inception, this fresh capital validates our vision and is a testament to our team's dedication to better serving clients and expanding into new markets.'
Article content
To be effective business partners, compensation and HR teams must maximize the value of their data, adapt to rapidly changing markets, and optimize workflows to ensure accuracy and consistency. BetterComp's platform enables this by automating daily tasks, supporting the creation of widely applicable custom formulas, and promoting a policy-based approach to data consumption and communications. Behind the scenes, it normalizes datasets and presents them in a clear, digestible format – freeing compensation professionals to focus on delivering informed, strategic pay decisions.
Article content
'We are thrilled to be part of BetterComp's journey to modernize and automate compensation management – an area that has long been overlooked by tech innovation,' said Steve Lula, Partner at Ten Coves Capital. 'We see tremendous value in what BetterComp is building and believe this team has the domain knowledge and network to create a market-leading company in the compensation industry.'
Article content
The funding comes on the heels of continued momentum for BetterComp throughout 2025, after achieving 100% YOY growth in each of the previous two years. Today, 38% of BetterComp's customers are Fortune 500 companies, and the company's headcount has grown 33% so far this year.
Article content
To learn more about BetterComp, visit bettercomp.com.
Article content
About BetterComp
Article content
BetterComp was founded by comp experts for comp experts to help businesses move faster, stay consistent, and make better-informed decisions. Prioritizing data agility and ease-of-use, BetterComp's software was developed to make the most out of market data and to ensure that the technology grows with their customers. To learn more about how BetterComp is modernizing and streamlining compensation practices, please visit bettercomp.com.
Article content
Ten Coves Capital backs high growth B2B software companies across the financial technology ecosystem where its capital, network, and decades of experience can help accelerate growth and value creation. Investing across payments, banking & lending, asset management, capital markets, and insurance & benefits (among other segments), the Ten Coves team has helped scale over 40 companies that are solving industry pain points, enabling workflows, and providing critical infrastructure to the largest financial institutions down to SMBs. For more information, visit tencoves.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
BetterComp Media Contact
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
12 minutes ago
- The Market Online
Why Celestica stock has been on a tear as of late
Celestica is a technology leader in design, manufacturing, hardware and supply chain solutions with a global presence spanning North America, Europe and Asia, and a client roster featuring some of the world's biggest brands The company's growing role as a data centre service provider has propelled revenue and profits higher since ChatGPT hit the scene in 2022 Celestica stock has soared in response, adding more than 1,700 per cent When OpenAI launched ChatGPT in 2022, it unleashed a global wave of interest and capital into artificial intelligence (AI), with companies across the industry spectrum scrambling to increase computing power and develop AI models to reach newfound levels of operational efficiency. This content has been prepared as part of a partnership with Celestica Inc., and is intended for informational purposes only. This frenzy has attracted some of the largest companies in the world, including Amazon, Alphabet and Meta, propelling each of them to multi-trillion-dollar market capitalizations, with Alphabet estimating that it will spend US$85 billion in 2025 on computing and AI to compete on the leading edge of data processing power. AI demand has also been favorable to picks-and-shovels players that have proven themselves to be reliable suppliers for the data centers developers need to test and deploy their projects. As a result, investors have candidates for due diligence for days, with US Money News and Yahoo! Finance hosting the most-viewed lists of prospective stocks on Google as of July 29. One supplier both fail to mention, Celestica (TSX:CLS), market capitalization C$32.16 billion, Canada's third-largest technology company, is a model for how strategic industry alignment can translate into shareholder value, with the stock having added more than 100 per cent year-to-date, more than 300 per cent year-over-year and more than 1,700 per cent since ChatGPT's debut, thanks to: Pre-ChatGPT data centre servicing contracts with Amazon, Alphabet and Meta. Margin expansion thanks to a shift towards proprietary products, following the arrival of chief executive officer Rob Mionis in 2015, with 43 per cent of its current line designed in house. A diversified client base across aerospace and defense, communications, enterprise, health technology, industrial and capital equipment. A turnkey service offering, from design to manufacturing to hardware platforms to supply chain solutions and full-scale production. The fact that AI, nascent as it may be, is delivering tangible value to companies across the board, saving time and resources, differentiating value propositions and pushing stock prices higher. Celestica has parlayed its prime position into impressive financials over the period, generating US$7.96 billion in revenue in 2023 and US$9.64 billion in 2024, backed up by net income of US$244.4 million and US$428 million, respectively, driven by rapidly accelerating demand. Q1 and Q2 2025 have been similarly value-accretive, delivering US$2.65 billion and US$2.89 billion in revenue, coupled with net income of US$86.2 million and US$211 million, respectively, with a robust demand outlook prompting the company to increase 2025 guidance twice over the period. The company expects to generate US$11.55 billion in revenue for the year, up from US$10.85 billion, and non-GAAP adjusted earnings per share of US$5.50, up from US$5. Celestica is further differentiated by pricing power. As confirmed in the Q2 news release, the company is positioned to recover almost all tariffs paid under US President Trump's regime from its customers, with no expected material impact to non-GAAP adjusted operating earnings or non-GAAP adjusted net earnings, demonstrating the insatiable demand for AI functionality running its way through every imaginable market. As Mionis put it in the Q2 earnings call, 'we continue to anticipate another year of solid financial performance for Celestica in 2025,' remaining 'confident in our ability to continue our strong momentum, even with the uncertainty in the current macro environment,' adding that 'we believe we are positioned to continue to excel and to sustain this positive momentum into 2026 and over the long term.' Given the multi-year upside potential at play with Celestica, investors have a chance to buy into what may prove to be a value price, despite what the company's share price of C$277.95 and price-to-earnings ratio of 46.5 may suggest at first glance. Join the discussion: Find out what investors are saying about this AI stock on the Celestica Inc. Bullboard, and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Cision Canada
2 hours ago
- Cision Canada
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
VANCOUVER, BC, July 29, 2025 /CNW/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving towards major milestones in AI-powered healthcare solutions, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Healthcare Triangle, Inc. (NASDAQ: HCTI), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Spectral AI, Inc. (NASDAQ: MDAI). According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the use of AI. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA's comments, has now been presented to Fortrea, the company's contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova's goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy. "We are committed to meeting the highest regulatory standards, and we're confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process." The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful. Meanwhile, Vision AI has gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners. Avant and Ainnova's FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically. Avant maintains global licensing rights to Ainnova's platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova's technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform. Renovaro Inc. (NASDAQ: RENB) secured multiple U.S. patents for its federated AI learning technologies in biomedical research. "Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro. These patents support secure, privacy-preserving data integration across hospitals and labs for applications in drug discovery and precision medicine. The move strengthens Renovaro's position in the $20 billion biomedical AI space. Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI-powered EHR services. Its platform converts unstructured medical documents into usable data for clinicians. "These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle." We're driving digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider." The company is focused on making EHR systems smarter, more efficient, and better suited to community health networks. GE HealthCare Technologies Inc. (NASDAQ: GEHC) launched its Definium Pace Select ET, an AI-powered digital X-ray system for high-volume medical settings. "This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President and CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging." The system automates repetitive tasks and improves image consistency to help radiologists work more efficiently. It's designed to relieve staffing pressures while maintaining high imaging standards in busy hospitals. Spectral AI, Inc. (NASDAQ: MDAI) submitted its DeepView System to the FDA for marketing approval under the De Novo pathway. "This FDA submission is a major milestone for Spectral AI and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the United States," said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. "It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes." The device uses multispectral imaging and AI to predict how burn wounds will heal, helping doctors make faster and more accurate treatment decisions. It's positioned as a first-of-its-kind diagnostic tool in burn care. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Globe and Mail
3 hours ago
- Globe and Mail
Why value investing has worked better outside the US
I recently interviewed investor and author Daniel Rasmussen for The Long View podcast, where he commented that 'value hasn't worked in the U.S., but it's worked fine internationally.' I was intrigued by this observation. So, I looked at Morningstar's indexes. Sure enough, value investing has prospered beyond American shores—this year, as well as over the past three-, five-, and 10-year periods. 'Magnificent Seven' vs. 'Granolas' US stocks of all styles have beaten international stocks for years, due to a strengthening dollar, superior returns on invested capital, and expanding price multiples. Morningstar's US growth index is dominated by the ' Magnificent Seven.' But internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion. There was a time when the ' Granolas ' stocks were being promoted as Europe's answer to the Magnificent Seven (names like GSK, Roche, Nestle, L'Oreal and AstraZeneca). But don't blame yourself if you haven't heard of the Granolas. They never really rivaled the Magnificent Seven from a performance perspective. So, what has boosted value investing internationally? Largely, the financial-services sector (which was lifted by higher interest rates) and energy stocks. Looking beyond Europe with style While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market capitalization outside the US. Rather, value stocks in emerging markets (like China, India, and Brazil) and developed Asia have outperformed by an even larger margin than in Europe. The decline of Chinese internet companies, which were once big growth stocks, helps explain why value investing has triumphed over growth investing in emerging markets in recent years. On the developed-markets side, Japan has seen rising interest rates and improved economic and investment conditions disproportionately benefit financial-services stocks, which tend to reside on the value side of the market. Value's underperformance in the US: Is it macro or micro? While I have mentioned some macroeconomic factors above, I am generally skeptical of attempts to explain style leadership from the top down. Back in 2022, when sticky inflation prompted the largest interest-rate hikes in a generation, US growth stocks fell much further than value. A popular narrative arose: Growth stocks are more sensitive to interest rates. But then growth bounced back in 2023 despite high rates. The Magnificent Seven and others rode a wave of enthusiasm for AI. Growth stocks' thriving amid higher rates is hardly unprecedented. Between 2015 and 2018, the US Federal Reserve hiked rates several times, yet growth beat value by a wide margin. Ultimately, I agree with Rasmussen that the triumph of growth over value in the US has more to do with 'historically unique and rare circumstances.' I've been following markets long enough to know that style leadership can be cyclical. Right now, it's value investing that's being fundamentally questioned. Value stocks have been called 'structurally challenged,' in 'secular decline,' and 'value traps.' But the value side of the market has always been home to troubled companies. Value investing is about stocks that under promise and overdeliver. Perhaps the long-term cycle will turn again in value's favor. AI could be revolutionary, but, like the internet, ahead of itself from an investment perspective. We could look back at 2025 as a historical inflection point, as marking a new market regime. The problem is that these things are only clear in retrospect. It will take time to know if the rotations we've seen in early 2025 will last, or if they're just head fakes. ____
